Humira's treatment of psoriasis is expected to be approved
-
Last Update: 2020-07-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
tumorthe necrosis factor blocker Humira is expected to be approved by the European Union within two months for the treatment of moderate-to-severe psoriasisAs a result, Humira's indications will be expanded from the first four indications (rheumatoid arthritis, psoriasis, hyperthermia and Crohn's disease) to fivePreviously, Humira conducted two clinical trials called REVEAL and CHAMPION for the new indicationsOf the 52 weeks of REVEAL, 1,200 were subjects, and the symptoms eased significantly after 16 weeks of drug use, with nearly three-quarters of people having psoriasis area and severity index of 75, compared with only 6.5 percent of the placebo control groupCHAMPION's 16-week trial involved 271 subjects, 80 percent of people who used Humira had a psoriasis area and severity index of 75, and only 36 percent of the subjects whostandardtherapy with metformin met the effect, compared with 20 percent in the placebo control groupHumira's third-quarter sales were $803 million, up 48.5 percentIndustry insiders believe that the new indications of moderate-to-severe psoriasis will further increase their sales after being approved(Wang Hai)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
